Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vaxart Inc VXRT

Healthcare Biotechnology
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its... see more

Recent & Breaking News (NDAQ:VXRT)

Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate

GlobeNewswire June 6, 2023

Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET

GlobeNewswire May 31, 2023

Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results  

GlobeNewswire May 4, 2023

Vaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4

GlobeNewswire April 28, 2023

Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6

GlobeNewswire March 29, 2023

Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus

GlobeNewswire March 17, 2023

Vaxart Provides Business Update and Full Year 2022 Financial Results

GlobeNewswire March 15, 2023

Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15

GlobeNewswire March 8, 2023

Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate

GlobeNewswire February 14, 2023

Vaxart Names Phillip Lee as Chief Financial Officer

GlobeNewswire December 19, 2022

Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers

GlobeNewswire December 1, 2022

Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29

GlobeNewswire November 22, 2022

Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results

GlobeNewswire November 8, 2022

Scott+Scott Attorneys at Law LLP and Hagens Berman Sobol Shapiro LLP Announce Pendency of Class Action To All Persons and Entities Who Purchased or Otherwise Acquired Shares of the Common Stock of Vaxart, Inc. During the Period Between June 15, 2020 and August 19, 2020, Inclusive

PR Newswire October 31, 2022

Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8

GlobeNewswire October 20, 2022

Vaxart to Present at World Vaccine Congress Europe 2022 on October 13

GlobeNewswire October 10, 2022

Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 7, 2022

Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

GlobeNewswire September 1, 2022

Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial

GlobeNewswire August 31, 2022

Vaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer

GlobeNewswire August 31, 2022